GlassScriptPhysician profile
Robin Risky
NPI 1073267266
$1,268.56
in general payments reported to CMS, 2019-2025
19 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $303 · 2024: $532 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $284.37 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $201.31 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $121.43 | 2023-2025 | |
| Lilly USA, LLC | $114.81 | 2023-2024 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $94.99 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $69.59 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $60.92 | 2025 | |
| Mannkind Corporation | $36.88 | 2023-2024 | Afrezza |
| Janssen Pharmaceuticals, INC | $35.61 | 2023-2024 | Xarelto |
| Ironwood Pharmaceuticals, INC | $35.41 | 2023-2024 | Linzess |
| Glaxosmithkline, LLC. | $32.99 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $31.90 | 2024-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $31.67 | 2024-2025 | Zoryve |
| Amgen INC. | $24.44 | 2023 | Repatha, Otezla |
| Tris Pharma INC | $21.64 | 2024 | Dyanavel Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.03 | 2023 | |
| Genzyme Corporation | $18.38 | 2024 | |
| Nevro Corp. | $16.61 | 2024 | Senza |
| Pfizer INC. | $15.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Risky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.